Mesna Cell

Mesna, the active ingredient in Mesna Cell, is a uroprotective agent presented as a solution for injection for intravenous use. It helps prevent hemorrhagic cystitis caused by cyclophosphamide and ifosfamide in adult and pediatric oncology patients receiving these chemotherapy agents.

GNH USA supplies Mesna Cell as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mesna is used as a uroprotective adjunct in chemotherapy regimens that generate toxic bladder metabolites.

Hemorrhagic cystitis (cyclophosphamide): Prevents bladder inflammation and bleeding associated with cyclophosphamide therapy. Hemorrhagic cystitis (ifosfamide): Reduces risk of bladder toxicity during ifosfamide treatment. Chemotherapy adjunct: Provides uroprotection as part of combination protocols to improve tolerability of alkylating agents.

Mesna may be associated with several adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis after infusion. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus. - Metallic taste: temporary alteration of taste perception. - Mild hypotension: slight drop in blood pressure during administration.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked blood pressure decline that may need intervention. - Pulmonary edema: fluid accumulation in lungs presenting with dyspnea. - Hemolysis: destruction of red blood cells leading to anemia. - Stevens‑Johnson syndrome: rare severe skin reaction.

When using Mesna, several precautions should be observed to ensure safety and effectiveness. Renal function: assess baseline kidney function and monitor during therapy. Hydration: maintain adequate fluid intake to promote urinary excretion of the drug. Concomitant chemotherapy: coordinate timing with cyclophosphamide or ifosfamide to achieve optimal protection. Allergy: discontinue immediately if signs of hypersensitivity appear. Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mesna can interact with other medicines, affecting its protective capacity or increasing toxicity.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin): combined use may heighten renal injury risk. - High‑dose thiotriazole compounds: may diminish Mesna’s ability to inactivate acrolein.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase urinary clearance of Mesna, requiring dose adjustment. - ACE inhibitors or ARBs: monitor blood pressure as additive hypotensive effect is possible. - Other uroprotective agents (e.g., sodium thiosulfate): assess for overlapping toxicity or additive benefit. - Antacids: may alter solution pH and affect stability of Mesna during preparation.